4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $29.56.

FDMT has been the topic of a number of research analyst reports. Royal Bank Of Canada reduced their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. Barclays reduced their price objective on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an "overweight" rating on the stock in a research note on Friday, May 9th. Chardan Capital reduced their price objective on shares of 4D Molecular Therapeutics from $28.00 to $25.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. HC Wainwright reiterated a "buy" rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, June 11th.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of FDMT. Dynamic Technology Lab Private Ltd bought a new position in shares of 4D Molecular Therapeutics in the 1st quarter worth about $39,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $41,000. AQR Capital Management LLC acquired a new stake in shares of 4D Molecular Therapeutics in the 1st quarter worth about $46,000. KLP Kapitalforvaltning AS acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $48,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of 4D Molecular Therapeutics in the 4th quarter worth about $50,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $4.00 on Wednesday. 4D Molecular Therapeutics has a one year low of $2.24 and a one year high of $28.93. The company has a 50 day moving average price of $3.64 and a 200 day moving average price of $4.35. The firm has a market capitalization of $185.32 million, a price-to-earnings ratio of -1.26 and a beta of 2.84.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 33.26% and a negative net margin of 767,126.06%. As a group, equities analysts forecast that 4D Molecular Therapeutics will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.